This article was accepted into the corpus but its outbound wikilinks were never NER-processed — typical at the deepest BFS hop or when the run's entity cap was reached. No expansion funnel to show.
| vitamin K epoxide reductase complex subunit 1 | |
|---|---|
| Name | VKORC1 |
| Uniprot | P0A799 |
| Organism | Homo sapiens |
vitamin K epoxide reductase complex subunit 1. Vitamin K epoxide reductase complex subunit 1 is a membrane-associated enzyme involved in the vitamin K cycle and in the post-translational modification of several Winnipeg Treaty-level proteins. It participates in a redox process that regenerates active vitamin K from its epoxide form and thereby enables gamma-glutamyl carboxylation required for blood coagulation. The protein’s activity influences clinical anticoagulation therapy and has been the focus of genetic, biochemical, and pharmacological research involving notable institutions and investigators.
VKORC1 catalyzes the reduction of vitamin K 2,3-epoxide to vitamin K quinone and then to vitamin K hydroquinone, sustaining the cofactor pool for the gamma-glutamyl carboxylase reaction that modifies glutamate residues on substrates such as coagulation factors. Its enzymatic cycle involves disulfide bond formation and reduction between conserved cysteine residues and accepts electrons from cellular redox partners located in the endoplasmic reticulum. The mechanism has been interrogated using mutagenesis and biochemical assays developed in laboratories affiliated with Max Planck Society, Howard Hughes Medical Institute, National Institutes of Health, Salk Institute, and Harvard Medical School. Structural and mechanistic models have also been informed by comparisons with membrane oxidoreductases characterized at centers like European Molecular Biology Laboratory and Cold Spring Harbor Laboratory.
VKORC1 is an integral membrane protein of the endoplasmic reticulum with multiple transmembrane helices. Topology models based on biochemical mapping and cryo-electron microscopy suggest a four-transmembrane-helix architecture with luminal and cytosolic loops that position conserved active-site cysteines for catalysis. Key residues and motifs have been identified through studies at institutions such as Massachusetts Institute of Technology, Yale University, University of Cambridge, Stanford University, and University of Oxford. Comparative sequence analysis places VKORC1 within a family distinct from bacterial quinone reductases characterized by researchers at Pasteur Institute and Max Planck Institute for Biophysical Chemistry, but sharing mechanistic parallels with membrane redox systems studied at Johns Hopkins University.
The VKORC1 gene resides on human chromosome regions studied alongside genes cataloged by the Human Genome Project and clinical databases maintained by Centers for Disease Control and Prevention and World Health Organization. Genetic variants in VKORC1 alter gene expression and enzyme activity through promoter polymorphisms, coding-sequence missense changes, and haplotypes that have been genotyped in cohorts coordinated by groups at University of California, San Francisco, Mayo Clinic, University of Pennsylvania, Karolinska Institutet, and Imperial College London. Transcriptional regulation involves endoplasmic reticulum stress pathways investigated in research programs at National Cancer Institute and European Research Council-funded consortia. Post-translational modifications and protein–protein interactions that influence VKORC1 stability have been explored in proteomics studies at Broad Institute and Riken.
Variants in VKORC1 are major determinants of interindividual variability in response to vitamin K antagonists and have been associated with bleeding disorders and altered coagulation profiles identified in clinical centers such as Cleveland Clinic and Mayo Clinic. Rare loss-of-function mutations produce vitamin K–dependent coagulation factor deficiency presenting with hemorrhagic disease in neonates and juveniles treated at tertiary care hospitals like Great Ormond Street Hospital and Boston Children’s Hospital. Population studies led by teams at Johns Hopkins Medicine, University of Toronto, University of Sydney, and Seoul National University have documented allele frequency differences across ethnic groups, informing guidelines from agencies such as Food and Drug Administration and European Medicines Agency. VKORC1 expression and variants have also been evaluated in association studies of cardiovascular disease cohorts overseen by institutions like Framingham Heart Study and UK Biobank.
VKORC1 is the pharmacological target of coumarin anticoagulants including warfarin, acenocoumarol, and phenprocoumon; binding of these inhibitors blocks the enzyme’s reductase activity and thereby reduces gamma-carboxylation of clotting factors. Genetic polymorphisms in VKORC1 contribute to dose variability and to warfarin resistance phenotypes characterized in clinical pharmacogenetics programs at St. Jude Children’s Research Hospital, Vanderbilt University Medical Center, University of California, Los Angeles, Mount Sinai Hospital, and Mayo Clinic Center for Individualized Medicine. Mechanistic studies of inhibitor binding and resistance mutations have been performed using biochemical reconstitution and cell-based assays developed at ETH Zurich and University of Basel. Clinical dosing algorithms that integrate VKORC1 genotypes with variants in CYP2C9 and other pharmacogenes have been promulgated by consortia including Clinical Pharmacogenetics Implementation Consortium and incorporated into guidelines from American College of Cardiology and American Heart Association.
Functional characterization of VKORC1 has employed yeast, bacterial, and mammalian model systems widely used at laboratories in University of California, Berkeley, Princeton University, University of Chicago, and University of Michigan. Knockout and transgenic mouse models generated and analyzed at facilities like Jackson Laboratory and Wellcome Sanger Institute have revealed the enzyme’s role in coagulation and embryonic development. Complementation studies using bacterial homologs were reported by teams at University of Texas Southwestern Medical Center and University of Illinois, and CRISPR-based perturbations in cell lines have been implemented in projects funded by National Science Foundation and Wellcome Trust. High-throughput chemical screens for novel VKORC1 modulators have been conducted in collaboration with industry partners including Pfizer, Roche, and Novartis.
Category:Human proteins